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The Extravesicular Domain of Synaptotagmin-1 Is Released
with the Latent Fibroblast Growth Factor-1 Homodimer in
Response to Heat Shock*
(Received for publication, March 9, 1998, and in revised form, June 13, 1998)
Francesca Tarantini‡, Theresa LaVallee§ §§, Anthony Jackson§§, Susan Gamble¶§§,
Carla Mouta Carreirai, Susan Garfinkel, Wilson H. Burgess**§§, and Thomas Maciag‡‡§§
From the Center for Molecular Medicine, Maine Medical Center Research Institute, South Portland, Maine 04106 and the
§§Department of Molecular Biology, Holland Laboratory, American Red Cross, Rockville, Maryland 20855
The heparin-binding fibroblast growth factor (FGF)
prototypes lack a classical signal sequence, yet their
presence is required in the extracellular compartment
for the activation of cell-surface receptor-dependent sig-
naling. Early studies with FGF-1 demonstrated its pres-
ence in bovine brain as a novel high molecular weight
complex, and subsequent studies identified a second he-
parin-binding protein that co-purified with FGF-1.
Polypeptide sequence analysis revealed that this hepa-
rin-binding protein corresponded to the extravesicular
domain of bovine synaptotagmin (Syn)-1, a transmem-
brane component of synaptic vesicles involved in the
regulation of organelle traffic. Since FGF-1 is released
in response to heat shock as a mitogenically inactive
Cys-30 homodimer, we sought to determine whether this
heparin-binding protein was involved in the release of
FGF-1. We report that a proteolytic fragment of the ex-
travesicular domain of Syn-1 is associated with FGF-1 in
the extracellular compartment of FGF-1-transfected
NIH 3T3 cells following temperature stress. By using
heparin-Sepharose affinity to discriminate between the
monomer and homodimer forms of FGF-1 and resolution
by conventional and limited denaturant gel shift immu-
noblot analysis, it was possible to identify FGF-1 and
Syn-1 as potential components of a denaturant- and re-
ducing agent-sensitive extracellular complex. It was
also possible to demonstrate that the expression of an
antisense-Syn-1 gene represses the release of FGF-1 in
response to heat shock. These data indicate that FGF-1
may be able to utilize the cytosolic face of conventional
exocytotic vesicles to traffic to the inner surface of the
plasma membrane where it may gain access to the ex-
tracellular compartment as a complex with Syn-1.
Fibroblast growth factor (FGF)1-1 (acidic) and FGF-2 (basic)
are the prototype members of the FGF gene family, and these
proteins have been extensively characterized as potent angio-
genic and neurotrophic factors (1). The FGF prototypes lack a
conventional signal peptide sequence for secretion through the
endoplasmic reticulum-Golgi-mediated pathway, yet their in-
teraction with high affinity tyrosine kinase receptors on the cell
surface implies the function of an alternative secretion path-
way to mediate their release.
We have previously reported that FGF-1 is actively released
from FGF-1-transfected NIH 3T3 cells by a transcription- and
translation-dependent mechanism in response to temperature
stress (2). Analysis of the effects of brefeldin A on the release of
FGF-1 in this system demonstrated the unconventional nature
of the FGF-1 release pathway since disruption of endoplasmic
reticulum-Golgi communication (3) did not inhibit the appear-
ance of extracellular FGF-1 in response to heat shock (4). In
addition, we have also reported the following: (i) FGF-1 is
released as a latent homodimer with reduced affinity for im-
mobilized heparin (5); (ii) the FGF-1 homodimer can be acti-
vated by treatment with either (NH4)2SO4 (2) or reducing
agents (4); (iii) FGF-1 homodimer formation utilizes residue
Cys-30, and dimer formation is important for FGF-1 release (5);
(iv) FGF-1 contains a phosphatidylserine-binding domain be-
tween amino acid residues 114 and 137 (5); (v) the release of
FGF-1 involves the function of a carboxyl-terminal domain
which is not present in FGF-2 (6); and (vi) the FGF-1 secretion
pathway does not restrict the release of high molecular weight
forms of FGF-1 since an FGF-1:b-galactosidase chimera is re-
leased as a structurally intact protein (6). The ability of FGF-1
to interact with phosphatidylserine (5), an important compo-
nent of the inner leaflet of the plasma membrane (7), implies
that this interaction may play a role in its release. Finally,
analysis of FGF-1 release using FGF-1:FGF-2 chimeric con-
structs demonstrated that FGF-1, but not FGF-2, is released in
response to temperature stress (6).
Early studies on the purification of FGF-1 from bovine brain
tissue demonstrated the presence of high and low molecular
weight forms of the protein; the high molecular weight form of
FGF-1 represents an acid-sensitive complex (8). During the
characterization of brain-derived FGF-1 as a heparin-binding
protein, a second polypeptide was identified that co-eluted with
FGF-1 from immobilized heparin (8). This protein was isolated,
sequenced, and identified as the extravesicular portion of syn-
* This work was supported by National Institutes of Health Grants
HL35627, HL54710, and HL32348 (to T. M.). The costs of publication of
this article were defrayed in part by the payment of page charges. This
article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
‡ Present address: Dept. of Geriatric Medicine, University of Flor-
ence, School of Medicine, Florence, Italy.
§ Present address: EntreMed, 9610 Medical Ctr. Dr., Rockville, MD
20850.
¶ This work was performed in partial fulfillment of the requirements
for the doctorate of philosophy from the Genetics Graduate Program,
George Washington University, Washington, D. C.
i This work was performed in partial fulfillment of the requirements
for the doctorate of philosophy from the Biochemistry and Molecular
Biology Dept ., George Washington University, Washington, D. C.
** Present address: Dept. of Tissue Biology, Holland Laboratory,
American Red Cross, 15601 Crabbd Branch Way, Rockville, MD 20855.
‡‡ To whom correspondence should be addressed: Center for Molec-
ular Medicine, Maine Medical Center Research Institute, 125 John
Roberts Rd., S. Portland, ME 04106. Tel.: 207-761-9783; Fax: 207-828-
8071; E-mail: maciat@mail.mmc.org.
1 The abbreviations used are: FGF, fibroblast growth factor; RT-PCR,
reverse transcription-polymerase chain reaction; PAGE, polyacryl-
amide gel electrophoresis; Syn, synaptotagmin; CM, conditioned me-
dium; DMEM, Dulbecco’s modified Eagle’s medium; DTT, dithiothre-
itol; HUVEC, human umbilical vein endothelial cells; 2-ME,
2-mercaptoethanol.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 273, No. 35, Issue of August 28, pp. 22209–22216, 1998
© 1998 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org 22209
aptotagmin (Syn)-1, an integral component of synaptic vesicles
(9). Because Syn-1 has been implicated in the regulation of
exocytotic (9) and endocytotic organelle trafficking (10), we
questioned whether Syn-1 may also be involved in the temper-
ature-dependent release of FGF-1. We now report the presence
of denaturant- and reducing agent-sensitive forms of FGF-1
and Syn-1 in media conditioned by heat shock from FGF-1-
transfected NIH 3T3 cells and have identified a p40 fragment
of Syn-1 as a potential component of the extracellular FGF-1
complex.
EXPERIMENTAL PROCEDURES
Cell Culture—Stable NIH 3T3 FGF-1 cell transfectants were ob-
tained as described previously (2) and maintained in Dulbecco’s modi-
fied Eagle’s medium (DMEM, Life Technologies, Inc.) on human fi-
bronectin (10 mg/cm2)-coated dishes containing 10% (v/v) bovine calf
serum (HyClone), 13 antibiotic/antimycotic (Life Technologies, Inc.),
and 400 mg/ml G418 (Life Technologies, Inc.). A confluent monolayer of
transfected cells was subjected to heat shock (42 °C for 2 h) in serum-
free DMEM, containing 4 units/ml heparin (The Upjohn Co.), as de-
scribed previously (2). Human umbilical vein endothelial cells were
grown as described previously (11).
Processing of Heat Shock Conditioned Media and Conventional and
Limited Denaturant Immunoblot Analysis—Conditioned medium was
collected after temperature stress (42 °C for 2 h), processed by filtra-
tion, and activated with either (NH4)2SO4 (2) or 0.1% (w/v) dithiothre-
itol (DTT, Sigma) (4). The DTT-treated conditioned medium was ad-
sorbed directly to a 1-ml heparin-Sepharose CL-6B column (Amersham
Pharmacia Biotech), previously equilibrated with 50 mM Tris, pH 7.4,
containing 10 mM EDTA (TEB), and the column was washed with TEB
and eluted with TEB containing increasing concentrations of NaCl. The
elution fractions were concentrated using a Centricon 10 concentrator
(Amicon, Inc.) and analyzed by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) under reducing conditions, as de-
scribed previously (4). The (NH4)2SO4-treated conditioned medium
(90% saturation) was recovered by centrifugation (9,000 3 g, 40 min),
resuspended in TEB, and processed over a 4-ml heparin-Sepharose
column previously equilibrated with TEB. The column was washed with
TEB and batch-eluted as 10-ml fractions with TEB containing increas-
ing concentrations of NaCl. Each post-heparin elution fraction was
divided into two samples to be analyzed by immunoblotting with either
the anti-FGF-1 or the anti-Syn-1 antibodies. Each sample was divided
again into two fractions of equal volume, concentrated using a Centri-
con 10 concentrator (Amicon, Inc.) to a final volume of 200 ml. Of the
first 200 ml, half was resuspended in an equal volume of SDS-PAGE
sample buffer (125 mM Tris, 2% SDS, 10% glycerol, and 0.1% bromphe-
nol blue) containing 2-mercaptoethanol (2-ME) and resolved by 15%
(w/v) conventional SDS-PAGE, and half was resuspended in SDS-PAGE
sample buffer without 2-ME and resolved by 15% conventional SDS-
PAGE. The second 200 ml were also divided in half, resuspended in an
equal volume of SDS-PAGE sample buffer with and without 2-ME, and
resolved using a limited denaturant electrophoretic gel shift system
(15% (w/v) acrylamide), where SDS was present in the sample and
running buffers but eliminated from the resolving gel (limited
SDS-PAGE).
Immunoblot analysis of the samples resolved by conventional and
limited SDS-PAGE was performed as described previously (2). Briefly,
after transfer to nitrocellulose filters, the filters were incubated in 24
mM Tris, pH 7.4, containing 136 mM NaCl, 2 mM KCl, and 0.1% (v/v)
Tween 20 (TCB) which also contained 5% (w/v) milk for 2 h at 42 °C and
were then washed 3 times with TCB. The filters were probed with either
a rabbit anti-human FGF-1 antibody (12) or with a rabbit anti-rat Syn-1
antibody, at a concentration of 1 mg/ml, for 1 h at room temperature and
then washed 3 times with TCB. The proteins were detected using the
ECL detection system (Amersham Pharmacia Biotech) following the
manufacturer’s instructions.
Purification of Recombinant Syn-1, Preparation of Syn-1 Antibody,
and Analysis of the Recombinant Syn-1 Heparin Binding Activity—A
rat Syn-1 construct (p65IIs) encoding amino acid residues 96–421 in
the expression vector pGEX-KG and two additional constructs, p65–123
(encoding amino acid residues 96–265) and p65–345 (encoding amino
acid residues 248–421), as glutathione S-transferase fusion proteins
were kindly provided by Dr. Richard Scheller (13) and used for the
preparation of antisera. The fusion proteins were generated and puri-
fied as described (13) except that a 50 mM Tris buffer, pH 8.8, containing
10 mM EDTA, 10 mM glucose, and 10 mg/ml lysozyme was used to lyse
BL21 Escherichia coli. The thrombin-cleaved proteins were further
purified by adsorption to heparin-Sepharose previously equilibrated in
50 mM phosphate buffer, pH 7.5, and eluted with a 0–1.5 M NaCl
gradient in 50 mM phosphate buffer, pH 7.5. Female, 6-month-old, New
Zealand White rabbits (Hazelton Research Animals) were injected in-
tradermally with 1 mg of protein suspended in Freund’s complete
adjuvant (Calbiochem), boosted with 200 mg of protein suspended in
incomplete Freud’s adjuvant (Calbiochem), and the antibodies purified
by incubating the serum with immobilized p65IIs on a Problot polyvi-
nylidene difluoride membrane (Applied Biosystems, Inc.) previously
blocked at 42 °C with TCB containing 5% (w/v) bovine serum albumin.
The membrane was washed 3 times with 0.05% (v/v) Triton X-100 in 50
mM Tris, pH 7.4, containing 150 mM NaCl, and the antibody was eluted
from the membrane with 0.2 M glycine, pH 2.8, and neutralized with 1
M K2HPO4, pH 7.4.
For the analytical study of the recombinant Syn-1 heparin-binding
affinity, 1 mg of thrombin-cleaved, p65IIs recombinant protein was
adsorbed to a 1-ml heparin-Sepharose column, previously equilibrated
with TEB. The column was washed with TEB and batch-eluted with 2.5
ml of TEB containing increasing concentrations of NaCl. The post-
heparin elution fractions were concentrated by Centricon to a final
volume of 50 ml and analyzed by conventional SDS-PAGE, under re-
ducing conditions. The protein was detected by immunoblot analysis
with a rabbit anti-rat Syn-1 antibody using the ECL detection system.
RT-PCR Analysis of the Syn-1 Transcript and Preparation of the NIH
3T3 Cell FGF-1 and Antisense-Syn-1 Co-transfectants—Total RNA from
FGF-1-transfected NIH 3T3 cells and human umbilical vein endothelial
cells (HUVEC) was isolated using the guanidinium isothiocyanate
method (14). As described previously (15), cDNA was obtained from 1
mg of total RNA and diluted to a final volume of 500 ml with H2O. PCR
was performed on 5 ml of cDNA in a 10 mM Tris buffer, pH 8.3,
containing 1 mM MgCl2, 50 mM KCl, 0.2 mM dNTPs, 2 units of Taq
polymerase, and 0.5 mg/each of sense (59-CCATTGCCACCGTGGGC-
CTT-39) and antisense (59-TCCAAAACAGTTACCACCAC-39) oligonu-
cleotide primers designed to recognize the human and the mouse Syn-1
sequences. PCR was performed for 35 cycles as follows: 1 min at 94 °C,
2 min at 54 °C, and 3 min at 72 °C. The PCR products were separated
from the oligonucleotide primers, unincorporated nucleotides, and Taq
polymerase using a Qiagen tip-5 column according to the manufactur-
er’s instructions (Qiagen PCR purification kit, Qiagen Inc.) and cloned
into a pCR 2.1 vector (TA cloning kit, Invitrogen) following the manu-
facturer’s instructions. The identity of the PCR fragments was then
confirmed by sequencing using the dideoxy sequencing method (Seque-
nase, U. S. Biochemical Corp.).
For the Syn-1 antisense gene construct, a rat Syn-1 gene into the
PCB1 vector (a gift from T. C. Sudhof (16)) was used to obtain the Syn-1
open reading frame that was cloned into a pCRTM II cloning vector
(Invitrogen) by PCR method, using the following primers: 59-GGGAGA-
CACGGGATCCTTACTTCTTGACAGCCAG-39 (sense oligonucleotide,
containing a BamHI restriction site) and 59-GCGACAGGAGCATATG-
GTGAGTGCCAGTCATCC-39 (antisense oligonucleotide, containing a
NdeI restriction site). A fragment encompassing the AUG initiator
codon and the first 640 nucleotides of the rat Syn-1 sequence was
obtained from the Syn-1/pCRTM II construct by digestion with the
restriction enzyme EcoRI, filling with DNA polymerase I large (Klenow)
fragment (Boehringer Mannheim) to obtain blunt ends, and a second
digestion with KpnI restriction enzyme. The product was purified by
agarose gel electrophoresis and ligated (T4 ligase, Life Technologies,
Inc.) in an antisense direction into HpaI/KpnI compatible ends of the
eukaryotic expression vector p39SS (LAC switch inducible mammalian
expression system, Stratagene). The anti-Syn-1/p39SS vector was trans-
fected into NIH 3T3 FGF-1 transfectants using the calcium phosphate
precipitation method. DMEM, containing 200 mg/ml hygromycin (Boeh-
ringer Mannheim) and 20% bovine calf serum, was used to select
hygromycin-resistant colonies. Colonies were screened for the expres-
sion of the anti-Syn-1 gene by Northern blot analysis using the anti-
Syn-1 fragment as probe.
Processing and Analysis of Heat Shock Conditioned Medium from
FGF-1 and Anti-Syn-1 Co-transfectants and Growth Assay—The FGF-1
transfectants and the FGF-1 and anti-Syn-1 co-transfectants were sub-
jected to temperature stress as described previously (2). Conditioned
media were treated with 0.1% DTT and adsorbed over a 1-ml heparin-
Sepharose column previously equilibrated with TEB. The column was
washed with TEB and the protein eluted with TEB containing 1.5 M
NaCl. The elution fractions were concentrated by Centricon, analyzed
by conventional SDS-PAGE under reducing conditions, and immuno-
blotted with anti-FGF-1 antibody as described previously. The proteins
recognized by the antibody were detected with an 125I-protein A probe.
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For the growth assay experiments, FGF-1 transfectants and FGF-1
and anti-Syn-1 co-transfectants were plated on 6-well cell culture
dishes at a concentration of 2 3 103 cells/well in DMEM, containing
increasing concentrations of bovine calf serum (0–20%). When the effect
of FGF-1 on the growth curve was analyzed, 5 ng/ml recombinant
FGF-1 and 4 units/ml heparin were added to the culture medium. At
day 7 the cells were trypsinized and counted with a Coulter counter.
RESULTS
Characterization of Bovine Brain-derived Synaptotagmin
(Syn)-1 as a Heparin-binding Protein Present in FGF-1 Prepa-
rations—FGF-1 was purified by heparin-Sepharose affinity
from bovine brain as described previously (8). The presence of
a second heparin-binding protein within the FGF-1 fraction,
which eluted with FGF-1 at 1.0 M NaCl, was detected by re-
versed phase high pressure liquid chromatography. The co-
eluted protein was characterized as a 40-kDa polypeptide by
SDS-polyacrylamide gel electrophoresis and subjected to auto-
mated Edman degradation. Interestingly, the amino-terminal
sequence of the p40 fragment corresponded to the extravesicu-
lar domain of synaptotagmin-1 (Syn-1) (9), starting in the
a-helical stretch proximal to its transmembrane domain (Fig.
1A). Syn-1 has been described as a neuronal-specific, integral
component of synaptic vesicles (9). It is considered to be the
calcium sensor of the regulated neurotransmitter secretory
pathway, and it displays potential docking properties through
its syntaxin-binding domain (17, 18). Interestingly, Syn-1 is
also able to interact with the clathrin AP-2 adaptor, participat-
ing in the clathrin-coated pit endocytotic pathway (10).
Since Syn-1 expression is considered to be neuron-specific,
we examined two non-neuronal cell culture systems for the
presence of the Syn-1 transcript. Analysis of human umbilical
vein endothelial cells and FGF-1 NIH 3T3 cell transfectants by
reverse transcription-polymerase chain reaction (RT-PCR) us-
ing human and murine Syn-1 primers demonstrated the pres-
ence of the Syn-1 transcript in both cell types (Fig. 1B). Se-
quence analysis of the human and murine RT-PCR products
confirmed the identity of these fragments as human and mu-
rine Syn-1 (data not shown).
A p40 Fragment of Syn-1 and the FGF-1 Monomer Are Pres-
ent in Heat Shock Conditioned Medium as Heparin-binding
Proteins—In order to define further the mechanism utilized by
FGF-1 for release, we employed stable FGF-1-transfected NIH
3T3 cells to determine whether the p40 proteolytic fragment of
Syn-1 was present in medium conditioned by temperature
stress. FGF-1 and Syn-1 immunoblot analysis was performed
on heparin-Sepharose fractions of medium conditioned by
FGF-1 transfectants during heat shock (42 °C, 2 h). Since
FGF-1 is released as a FGF-1 Cys-30 homodimer (4), the con-
ditioned medium was initially treated with 0.1% w/v dithio-
threitol (DTT) and resolved by heparin affinity-based chroma-
tography prior to conventional immunoblot analysis under
reducing conditions. As shown in Fig. 2A, the FGF-1 monomer
was detected in the high NaCl elution fractions (0.6 to 1.5 M
NaCl). Because the FGF-1 homodimer has been shown to elute
from immobilized heparin near 0.4 M NaCl (19) and FGF-1 was
undetectable in the low NaCl elution fractions (Fig. 2A), we
suggest that DTT treatment of media conditioned by heat
shock was effective in reducing the FGF-1 homodimer to mon-
omer. In addition, Syn-1 immunoblot analysis of the same
heparin-Sepharose elution fractions by conventional SDS-poly-
acrylamide gel electrophoresis (SDS-PAGE) under reducing
conditions also resolved the presence of a p40 fragment of
Syn-1 in the high NaCl elution fractions (0.8 to 1.0 M NaCl)
(Fig. 2B). These data suggest that p40 Syn-1 and FGF-1 were
both present in DTT-treated heat shock conditioned medium
from FGF-1-transfected NIH 3T3 cells and define their respec-
tive heparin-Sepharose elution profiles.
Recombinant Rat p40 Syn-1 Exhibits Similar Heparin Bind-
ing Affinity to the Protein Derived from NIH 3T3 Cell Medium
Conditioned by Heat Shock—Since Syn-1 has been previously
described as a heparin-binding protein with very high heparin
FIG. 1. The Syn-1 domain structure and the expression of the Syn-1 transcript in non-neuronal cells. A, the domain structure of Syn-1
is represented. N represents the Syn-1 NH2-terminal region (intravesicular oriented); TM, the transmembrane region; A, the first C2 domain,
homologous to the regulatory region of protein kinase C; B, the second C2 domain, and C, the COOH-terminal region (extravesicularly oriented).
The amino-terminal sequence of the p40 fragment that co-purified with FGF-1 from bovine brain preparations (b) is aligned with the published
sequence of bovine synaptotagmin-1 (a). As demonstrated by the alignment, the amino-terminal sequence of the p40 fragment corresponds to the
extravesicular portion of synaptotagmin-1, cleaved near its transmembrane region in the extravesicular domain. B, total RNA was purified from
a confluent monolayer of HUVEC or FGF-1-transfected NIH 3T3 cells. RNA (1 mg) was used for the reverse transcriptase reaction. Sense and
antisense primers for the human and the mouse Syn-1 sequences, as described under “Experimental Procedures,” amplified a 928-base pair PCR
product. Human glyceraldehyde-3-phosphate dehydrogenase or human b-actin-specific primers were also used to amplify the same cDNA as
control. The products of amplification were resolved on a 1% agarose gel and stained with ethidium bromide. Lanes 1 and 4, molecular weight
markers; lane 2, Syn-1 PCR product from HUVEC cDNA; lane 3, glyceraldehyde-3-phosphate dehydrogenase control; lane 5, Syn-1 PCR product
from FGF-1 transfectants; lane 6, b-actin control.
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affinity, eluting from immobilized heparin near 1.5 M NaCl
(20), we sought to confirm its heparin-binding characteristics.
A rat p40 Syn-1 fragment encoding amino acid residues 96–
421, which is very similar to the extravesicular domain of the
p40 Syn-1 fragment isolated from bovine brain (Fig. 1), was
expressed as a prokaryotic recombinant protein, and its hepa-
rin affinity was examined. As shown in Fig. 3, the recombinant
form of rat Syn-1 eluted from heparin-Sepharose between 0.6
and 0.8 M NaCl (Fig. 3). These data demonstrate that treatment
of heat shock conditioned medium with DTT generates a p40
fragment of Syn-1 with heparin binding affinity similar to the
prokaryotic recombinant p40 fragment.
Treatment of Heat Shock Conditioned Medium with
(NH4)2SO4 Reveals the Presence of Reducing Agent-sensitive
Forms of p40 Syn-1 and FGF-1 with Low Heparin Binding
Affinity—It has been demonstrated previously that the latent,
dimeric form of FGF-1 released into conditioned medium under
temperature stress is not biologically active in mitogenic as-
says and requires activation with either DTT or (NH4)2SO4 to
restore its mitogenic potential (4). Since DTT treatment of
medium conditioned by heat shock is able to generate a p40
Syn-1 fragment with similar heparin affinity as that exhibited
by the recombinant p40, we sought to determine the heparin
elution profile of extracellular FGF-1 and p40 Syn-1 when
medium conditioned by temperature stress was treated with
(NH4)2SO4. The samples obtained from heparin-Sepharose elu-
tion after treatment of conditioned medium with (NH4)2SO4
were independently examined for the presence of FGF-1 (Fig.
4) and Syn-1 (Fig. 5) by immunoblot analysis. Whereas immu-
noblot analysis performed after conventional SDS-PAGE under
reducing conditions revealed the presence of monomeric FGF-1
in the low and high NaCl elution fractions (Fig. 4A), the ap-
pearance of p40 Syn-1 was limited to the low NaCl elution
fractions (Fig. 5A). In contrast, FGF-1 (Fig. 4B) immunoblot
analysis performed after conventional SDS-PAGE under non-
reducing conditions demonstrated that the presence of the
FGF-1 monomer was restricted to the high NaCl elution frac-
tions and revealed the presence of high molecular weight
FGF-1 immunoreactive bands in the low NaCl elution fractions
(Fig. 4B). Similarly, Syn-1 immunoblot analysis of the heat
shock-conditioned, post-heparin-Sepharose samples resolved
by conventional SDS-PAGE under non-reducing conditions
(Fig. 5B) also detected the presence of high molecular weight
bands in the low NaCl elution fractions. These data indicate
the following: (i) a p40 fragment of Syn-1, as well as FGF-1, is
detected in the low NaCl elution samples of conditioned media
treated with (NH4)2SO4, but not DTT, and (ii) the electro-
phoretic mobility of both FGF-1 and p40 Syn-1 present in the
low salt elution fractions is sensitive to the presence of reduc-
ing agent. Thus, it is likely that the monomeric forms of FGF-1
and Syn-1 detected as high affinity heparin-binding proteins in
the high salt elution fractions of conditioned medium following
DTT treatment may represent the reduced products of the low
affinity heparin-binding forms of FGF-1 and Syn-1 present in the
low NaCl elution fractions from medium treated with (NH4)2SO4.
Treatment of Heat Shock Conditioned Medium with
(NH4)2SO4 Reveals the Presence of Denaturant-sensitive Forms
of p40 Syn-1 and FGF-1—Because both Syn-1 (16) and FGF-1
(5) are able to associate with the acidic phospholipid, phos-
phatidylserine, we examined the possibility that the electro-
phoretic mobility of p40 Syn-1 and FGF-1 detected in the low
NaCl elution fractions was also sensitive to the presence of the
detergent, SDS. Medium conditioned by heat shock was treated
with (NH4)2SO4, and the post-heparin-Sepharose elution sam-
ples were resolved under limited denaturant electrophoretic
conditions (limited SDS-PAGE) in which SDS was removed
from the running gel but was present in the sample and run-
ning buffers. As shown in Fig. 4C, immunoblot analysis of the
post-heparin-Sepharose elution fractions resolved by limited
SDS-PAGE detected the presence of the FGF-1 monomer in
FIG. 2. Immunoblot analysis of FGF-1 and Syn-1 in medium conditioned by heat shock after DTT treatment and heparin-
Sepharose affinity chromatography. Heat shock conditioned medium from NIH 3T3 FGF-1 transfectants was collected, treated with 0.1%
DTT, and processed over a heparin-Sepharose column as described under “Experimental Procedures.” Fractions were eluted with increasing
concentrations of NaCl and concentrated by Centricon to a final volume of 100 ml. Each fraction was resuspended with SDS-PAGE loading buffer
containing 2-ME and resolved by conventional 15% acrylamide SDS-PAGE. Immunoblot analysis was performed using an ECL detection system
as described under “Experimental Procedures.” Lane 1, 0.2 M NaCl elution fraction; lane 2, 0.4 M NaCl elution fraction; lane 3, 0.6 M NaCl elution
fraction; lane 4, 0.8 M NaCl elution fraction; lane 5, 1.0 M NaCl elution fraction; lane 6, 1.5 M NaCl elution fraction; lane 7, 50 ng of FGF-1b
recombinant protein (A), 50 ng of Syn-1 recombinant protein (B). A, FGF-1 immunoblot analysis; B, Syn-1 immunoblot analysis.
FIG. 3. Heparin binding characteristics of recombinant p40
Syn-1. A recombinant p40 Syn-1 fragment encoding amino acid resi-
dues 96–421 expressed as a glutathione S-transferase (GST) fusion
protein was obtained as described under “Experimental Procedures.”
The thrombin-cleaved material (2 mg) was adsorbed to the heparin-
Sepharose resin and eluted with increasing concentrations of NaCl. The
elution fractions were concentrated by Centricon, resuspended in SDS-
PAGE sample buffer containing 2-ME and resolved by 15% SDS-PAGE.
Syn-1 immunoblot analysis was performed using an ECL detection
system as described under “Experimental Procedures.” Lane 1, 0.2 M
NaCl elution fraction; lane 2, 0.4 M NaCl elution fraction; lane 3, 0.6 M
NaCl elution fraction; lane 4, 0.8 M NaCl elution fraction; lane 5, 1.0 M
NaCl elution fraction; lane 6, 1.5 M NaCl elution fraction. The doublet
character for the recombinant rat Syn-1 is similar to that previously
described (27).
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both the low and high NaCl elution fractions. Similarly, Syn-1
immunoblot analysis under the same conditions also detected
the presence of the p40 Syn-1 fragment in the low NaCl elution
fractions (Fig. 5C). Thus, both conventional and limited dena-
turant SDS-PAGE analysis performed under reducing condi-
tions demonstrated the presence of the FGF-1 monomer and
the p40 Syn-1 fragment in the low NaCl elution fractions.
However, when FGF-1 and Syn-1 immunoblot analysis was
performed under limited denaturant, non-reducing conditions,
the electrophoretic mobility of both FGF-1 (Fig. 4D) and Syn-1
(Fig. 5D) present in the low NaCl elution fractions was signif-
icantly impaired. In contrast, the electrophoretic mobility of
human FGF-1 (Fig. 4D) and rat p40 Syn-1 (Fig. 5D) recombi-
nant proteins as well as the molecular weight standards were
not altered by these electrophoretic conditions. These data
suggest that the electrophoretic mobility of FGF-1 and p40
Syn-1 present in the (NH4)2SO4-treated, low-heparin affinity
fractions was sensitive to the presence of both denaturant and
reducing agents.
The FGF-1 (Fig. 4, A–C) and Syn-1 (Fig. 5, A–C) immunoblots
also revealed the presence of additional bands running between
the 43- and the 67-kDa molecular mass standards. These bands
were not detected in the FGF-1 (Fig. 4D) and Syn-1 (Fig. 5D)
elution samples resolved under limited denaturant, non-reduc-
ing conditions in which all the bands run above the 97-kDa
molecular mass marker. Since the mobility of either recombi-
nant FGF-1 or recombinant Syn-1 was not altered by these
electrophoretic conditions, we suggest that the additional
bands detected in Figs. 4 and 5 (A–C) may represent either
reducing agent- and/or denaturant-sensitive complexes be-
tween monomeric FGF-1 and the p40 fragment of Syn-1 or may
reflect the presence of an additional moiety complexed with
FGF-1 and/or Syn-1. Alternatively, both Syn-1 and FGF-1 are
able to associate with phosphatidylserine (5, 16), and as a
result, it is possible that the presence of phosphatidylserine in
these samples may be responsible for the electrophoretic be-
havior of some of these bands. Since only monomeric FGF-1
and p40 Syn-1 were detected by immunoblot analysis in the
post-heparin elution fractions of media treated with DTT, the
presence of any additional high molecular weight band in Figs.
4 and 5 (A–D) confirmed the decreased efficiency of (NH4)2SO4
to release FGF-1 and Syn-1 as monomeric high affinity hepa-
rin-binding proteins.
The Co-expression of an Antisense Syn-1 Construct in NIH
3T3 Cell FGF-1 Transfectants Represses the Release of FGF-1
in Response to Heat Shock—Since the extravesicular p40 frag-
ment of Syn-1 and FGF-1 appears to be released into the
extracellular compartment in response to heat shock as a de-
FIG. 4. FGF-1 immunoblot analysis
of reducing agent- and denaturant-
sensitive forms of FGF-1 in medium
conditioned by heat shock after
(NH4)2SO4 treatment and heparin-
Sepharose affinity chromatography.
Heat shock CM from NIH 3T3 FGF-1
transfectants was collected, treated with
(NH4)2SO4, and processed over a heparin-
Sepharose column as described under
“Experimental Procedures.” Fractions
were collected, divided into two samples,
and concentrated by Centricon to a final
volume of 200 ml as described under “Ex-
perimental Procedures.” The first sample
was further divided in half, resuspended
in an equal volume of SDS-PAGE loading
buffer with 2-ME (A) or without 2-ME (B),
and resolved by traditional 15% acryla-
mide SDS-PAGE. The second sample was
further divided in half, resuspended in an
equal volume of SDS-PAGE loading
buffer with 2-ME (C) or without 2-ME (D),
and resolved by limited SDS-PAGE.
FGF-1 immunoblot analysis was per-
formed using an ECL detection system as
described under “Experimental Proce-
dures.” Lane 1, 0.2 M NaCl elution frac-
tion; lane 2, 0.4 M NaCl elution fraction;
lane 3, 0.6 M NaCl elution fraction; lane 4,
0.8 M NaCl elution fraction; lane 5, 1.0 M
NaCl elution fraction; lane 6, 1.5 M NaCl
elution fraction; lane 7, 50 ng FGF-1 re-
combinant protein.
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naturant- and reducing agent-sensitive complex, we sought to
determine whether the release of FGF-1 required the expres-
sion of Syn-1. We employed an antisense Syn-1 strategy to
repress Syn-1 protein expression in FGF-1-transfected NIH
3T3 cells and utilized an antisense rat Syn-1 transcript encom-
passing the AUG initiator codon and 640 nucleotides of the
Syn-1 open reading frame. Stable co-transfectants were ex-
panded and screened by Northern blot analysis using a rat
Syn-1 sense probe (data not shown). While under selection, it
became evident that the NIH 3T3 cell co-transfectants were
growth-impaired, and as a result, the FGF-1 and antisense
Syn-1 co-transfectants were analyzed for their proliferative
potential (Fig. 6A). Although NIH 3T3 cell FGF-1 transfectants
responded to the addition of serum, the NIH 3T3 cell FGF-1
and antisense Syn-1 co-transfectants exhibited a significant
attenuation of growth in response to serum. Interestingly, the
addition of exogenous FGF-1 to the NIH 3T3 cell FGF-1 and
Syn-1 co-transfectants resulted in a 30% increase in their abil-
ity to proliferate in response to serum (Fig. 6B). To our knowl-
edge, this is the first report of an FGF-1-independent cell line
exhibiting sensitivity to this growth factor in the presence of
high concentrations of serum. Moreover, the FGF-1 and anti-
sense Syn-1 co-transfected NIH 3T3 cells were not able to
release FGF-1 in response to heat shock (Fig. 6C). These data
indicate that Syn-1 expression is not only important for the
serum-dependent proliferation of NIH 3T3 cells but also for the
release of FGF-1 in response to temperature stress.
DISCUSSION
Eleven members of the Syn gene family have been identified
in both neuronal as well as non-neuronal tissues (21). As shown
in Fig. 1, Syn-1 contains a short intravesicular domain, a
transmembrane region, and a larger extravesicular, intracyto-
solic domain. The extravesicular domain contains two repeats
that are homologous to the C2 regulatory domain of protein
kinase C (9). The first C2 region (C2A) includes the Ca21-de-
pendent phospholipid-binding domain of Syn-1 (16), and the
second C2 domain (C2B) is responsible for the interaction with
the clathrin AP adaptor that enables Syn-1 to participate in the
clathrin-coated pit endocytotic pathway of cell-surface receptor
recycling (10). In addition, Syn-1 has the potential to function
as a docking protein through a carboxyl-terminal syntaxin-
binding domain (18). A role for Syn-1 in the regulation of
conventional endoplasmic reticulum-Golgi apparatus-depend-
ent secretion has already been suggested in pancreatic endo-
crine cells (22), and most of the proteins that comprise the
neurotransmitter secretory machinery have homologs in yeast
(23). These observations suggest that Syn-1 may be fundamen-
tally involved in the regulation of more general endocytotic and
exocytotic processes other than the highly specialized neuro-
transmitter release pathway. Indeed, structural confirmation
of the Syn-1 transcript in NIH 3T3 cell FGF-1 transfectants
and in human umbilical vein endothelial cells supports this
premise.
FIG. 5. Syn-1 immunoblot analysis
of reducing agent- and denaturant-
sensitive forms of Syn-1 in medium
conditioned by heat shock after
(NH4)2SO4 treatment and heparin-
Sepharose affinity chromatography.
Heat shock CM from NIH 3T3 FGF-1
transfectants was collected, treated with
(NH4)2SO4, and processed over a heparin-
Sepharose column as described under
“Experimental Procedures.” Fractions
were collected, divided into two samples,
and concentrated by Centricon to a final
volume of 200 ml as described under “Ex-
perimental Procedures.” The first sample
was further divided in half, resuspended
in an equal volume of SDS-PAGE loading
buffer with 2-ME (A) or without 2-ME (B),
and resolved by traditional 15% acrylam-
ide SDS-PAGE. The second sample was
further divided in half, resuspended in an
equal volume of SDS-PAGE loading
buffer with 2-ME (C) or without 2-ME (D),
and resolved by limited SDS-PAGE.
Syn-1 immunoblot analysis was per-
formed using ECL detection system as de-
scribed under “Experimental Proce-
dures.” Lane 1, 0.2 M NaCl elution
fraction; lane 2, 0.4 M NaCl elution frac-
tion; lane 3, 0.6 M NaCl elution fraction;
lane 4, 0.8 M NaCl elution fraction; lane
5,1.0 M NaCl elution fraction; lane 6, 1.5 M
NaCl elution fraction; lane 7, 50 ng of
Syn-1 recombinant protein.
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The presence of a p40 fragment of Syn-1 in medium condi-
tioned by heat shock is interesting since Syn-1 exists as a p65
transmembrane protein (Fig. 1A). Since the Syn-1 antibody
used in this study was raised against the recombinant extrave-
sicular domain of Syn-1 containing residues 96–421, it is likely
that the p40 Syn-1 fragment observed in the medium condi-
tioned by heat shock represents the extravesicular domain of
the p65 Syn-1 translation product. This is especially notewor-
thy because it implies the function of a cytosolic protease that
may be responsible for the generation of extravesicular p40
Syn-1 fragment under temperature stress. The protease activ-
ity would result in the cleavage of the p65 Syn-1 translation
product in a region adjacent to its transmembrane domain with
subsequent release of the p40 fragment from its transmem-
brane constraint. This event would also serve to dissociate p65
Syn-1 from its normal role in intracellular vesicular trafficking.
In addition, the sequence of the NH2-terminal region of the p40
fragment that was originally isolated from bovine brain in
association with FGF-1 indicates that this proteolytic cleavage
site does correspond to the known trypsin cleavage site already
described for p65 Syn-1 in bovine chromaffin granules (24).
This observation further supports the hypothesis that a novel
intracellular protease may be involved in the regulation of the
FGF-1 release pathway.
The data obtained from the NIH 3T3 cell FGF-1 and anti-
sense-Syn-1 co-transfectants are also significant since they
suggest that not only is Syn-1 expression important for FGF-1
release in response to heat shock, but Syn-1 expression is
important for the serum-induced proliferation of the NIH 3T3
cell. Since Syn-1 is involved in the regulation of cell-surface
receptor recycling through the conventional clathrin-coated pit
endocytotic pathway (10), it is possible that the repression of
Syn-1 expression may interrupt the recycling of receptors in-
volved in the maintenance of cellular nutrition. Thus, the at-
tenuation of Syn-1 expression may obstruct transferrin recep-
tor and/or the low density lipoprotein receptor systems and
possibly others, which may result in a non-lethal nutritional
defect with a proliferation-impaired phenotype. Alternatively,
the repression of Syn-1 expression may also prevent the endog-
enous release of FGF-1 from the NIH 3T3 cell which may be
important for the maintenance of cell survival. Indeed, the FGF
prototypes are well recognized as cell survival factors for a
variety of cell types in vitro (1), and since the NIH 3T3 cell
expresses levels of FGF-1 below the sensitivity of our analytical
methods (25), it is experimentally difficult to examine this
premise. However, because the addition of exogenous FGF-1 to
the NIH 3T3 cell FGF-1 and antisense-Syn-1 co-transfectants
only rescued approximately 30% of their serum-induced prolif-
erative potential, it is likely that a combination of these events
is responsible for the impaired proliferative potential of these
co-transfectants.
While the mechanism utilized by the FGF-1 homodimer and
FIG. 6. Growth response and FGF-1 immunoblot analysis of medium conditioned by heat shock from NIH 3T3 cell FGF-1 and
FGF-1 and anti-Syn-1 co-transfectants, following DTT treatment and heparin-Sepharose affinity chromatography. A, FGF-1 and
FGF-1 and anti-Syn-1 NIH 3T3 cell co-transfectants were plated into 6-well tissue culture dishes and grown in DMEM containing increasing
concentrations of BCS as described under “Experimental Procedures.” After 7 days in vitro, the cells were harvested and quantitated as described
under “Experimental Procedures”. B, recombinant FGF-1 (5 ng/ml) heparin (4 units/ml) were added to the medium to evaluate the effect of FGF-1
on the growth curve. After 7 days the cells were harvested by trypsin treatment and quantitated as described under “Experimental Procedures.”
Open bars represent the FGF-less control, and closed bars represent the FGF-1 response. C, heat shock CM from NIH 3T3 FGF-1 and FGF-1 and
anti-Syn-1 co-transfectants were collected, treated with 0.1% DTT, and processed over a heparin-Sepharose column as described under “Experi-
mental Procedures.” Elution fractions containing increasing concentration of NaCl were collected, concentrated by Centricon to a final volume of
100 ml, resuspended with SDS-PAGE loading buffer containing 2-ME, and resolved by conventional 15% acrylamide SDS-PAGE system. The FGF-1
released in CM was detected using a 125I-protein A detection system as described under “Experimental Procedures.” Medium from cells maintained
at 37 °C served as a negative control. FGF-1 immunoblot analysis of FGF-1 transfectants lysate (lane 1); FGF-1 and anti-Syn-1 co-transfectants
lysate (lane 2); FGF-1 transfectants 37 °C CM (lane 3); FGF-1 and anti-syn-1 co-transfectants 37 °C CM (lane 4); FGF-1 transfectants 42 °C CM
(lane 5); and FGF-1 and anti-syn-1 co-transfectants 42 °C CM (lane 6).
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the p40 Syn-1 fragment to pass through the lipid bilayer re-
mains unknown, our data do indicate that in response to tem-
perature stress, FGF-1 may associate with the cytosolic face of
Syn-1-containing exocytotic vesicles and may utilize this ex-
travesicular orientation for transport to the plasma membrane.
Since both FGF-1 and Syn-1 are able to associate with phos-
phatidylserine, an acidic phospholipid present on the inner
surface of plasma membranes (5, 16), it is possible that this
orientation may facilitate their release. Indeed, it will be inter-
esting to determine whether the p40 Syn-1 fragment is able to
attain molten globule character as described previously for
FGF-1 (26) which may enable it to associate with, and possibly
transverse, acidic phospholipid-rich membranes.
Our data demonstrate that the extracellular FGF-1 complex
released from NIH 3T3 cell FGF-1 transfectants in response to
temperature stress is likely composed of at least the p40 frag-
ment of Syn-1 and the FGF-1 homodimer. Whereas treatment
of this complex with DTT efficiently generates the p40 Syn-1
fragment and the FGF-1 monomer as high affinity heparin-
binding proteins, treatment with (NH4)2SO4 does not. Interest-
ingly, (NH)2SO4 treatment yields both the FGF-1 and the p40
Syn-1 fragment as low affinity heparin-binding proteins. How-
ever, FGF-1, but not the p40 fragment of Syn-1, is detected as
monomeric high affinity heparin-binding protein after the
(NH4)2SO4 treatment of media. Indeed, the high affinity hep-
arin-binding form of p40 Syn-1 is not present following treat-
ment with (NH4)2SO4. Although it is possible that the effect of
(NH4)2SO4 treatment may be derived from the ability of
(NH4)2SO4 to alter an unknown redox system in the extracel-
lular compartment, it is unlikely. Although we do not know the
mechanism utilized by (NH4)2SO4 to release the FGF-1 mono-
mer from the extracellular complex, we suggest that perhaps
both the FGF-1 monomer and homodimer may be associated
with the p40 Syn-1-containing complex. However, it is impor-
tant to emphasize that if the FGF-1 monomer is also present in
the extracellular complex, it is maintained in a form that does
not enable it to associate with cell-surface FGF receptors
and/or the heparin sulfate proteoglycan, since the FGF-1 pres-
ent in medium conditioned by temperature stress is not able to
associate with immobilized heparin and is not mitogenic (2).
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